查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1451397

2024-2032 年按來源、產品、疾病、製造和地區分類的生物製品市場報告

Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2023年全球生物製品市場規模達3,496億美元。展望未來， IMARC Group預計到2032年市場規模將達到6,995億美元，2024-2032年複合年成長率（CAGR）為7.8%。慢性病盛行率不斷上升，需要更有效的治療方案，不斷的技術進步促進了越來越有針對性的療法的開發，以及先進的藥物傳輸系統的出現，這些都是推動市場發展的一些因素。

生物製劑是源自活細胞的複雜分子，用於診斷、治療和預防疾病。這些分子與小分子藥物有著根本的不同，不僅在尺寸上，而且在結構的複雜性上。這些藥物解決方案具有高度特異性的特點，經過專門設計，可與人體內的特定成分（例如細胞和蛋白質）相互作用。這一獨特的屬性使它們能夠更精確地針對疾病途徑，提供更高的療效潛力，同時最大限度地減少副作用。其工作機制通常涉及透過阻斷或增強天然分子的活性來調節生物途徑，以恢復生理功能或消除病理因子。

這些複雜分子的全球市場主要是由慢性病盛行率上升所推動的，這需要更有效的治療選擇。與此一致的是，不斷的技術進步促進了越來越有針對性的療法的開發，這反過來又為市場提供了動力。此外，不斷擴大的醫療保健預算導致對先進治療方案的持續需求，成為重要的成長誘導因素。除此之外，向個人化醫療的轉變導致客製化療法的採用率更高，從而進一步擴大了市場。促進市場成長的其他一些因素包括知情且受過教育的患者基礎、人工智慧在藥物發現中的最佳化作用、生物製藥實體之間的策略合作，以及隨著非專利版本變得更容易被更大的人使用而出現的生物相似藥的出現。人口。

生物製品市場趨勢/促進因素：

標靶治療持續創新

複雜分子市場的一個重要驅動力是標靶治療的持續創新。這些療法旨在專門作用於某些導致疾病的細胞或分子，從而提高治療效果，同時最大限度地減少副作用。鑑於癌症和自體免疫疾病等疾病的嚴重性，標靶治療提供了一種新穎有效的治療途徑。廣泛的科學研究使人們能夠在分子層面上了解疾病機制，為比傳統方法更有效、毒性更小的專門治療方法鋪平了道路。隨著研發投資的增加，加上對個人化醫療的高度關注，這些標靶療法有望成為主流。它們的推出和隨後的成功可以大大提高對複雜分子的需求，從而成為市場的關鍵驅動力。

先進藥物輸送系統的出現

藥物輸送系統在醫療保健中發揮越來越重要的作用，通常決定複雜分子治療的有效性和患者依從性。該領域的創新有多種形式，從控釋機製到基於奈米技術的輸送系統。這些進步使患者更容易堅持治療方案，進而改善臨床結果。例如，較新的輸送系統可能會以每週甚至每月劑量取代每日注射，大大提高患者的便利性和繼續治療的意願。大量投資正在流入這些技術的研究和開發，目的是最大限度地提高複雜分子的治療效果。藥物輸送系統的這些進步極大地增強了市場的彈性和成長潛力，滿足了對更有效和對患者友好的治療選擇的需求。

監管變化和協調

長期以來，對於醫療保健產業的公司來說，穿越迷宮般的監管環境一直是一項艱鉅的挑戰。然而，當前監管協調的趨勢正在簡化這一複雜的情況。透過不同國家統一或相互認可的核准流程，市場准入障礙大大降低。這意味著新產品和現有產品可以比以前更快地覆蓋更廣泛的患者群體。其影響是多方面的：不僅加快了向患者提供這些創新療法的速度，而且這些產品的地理覆蓋範圍也顯著擴大。透過加速核准和擴大市場准入，這種有利的監管實踐協調正在推動複雜生物分子全球市場的大幅持續成長。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球生物製品市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依來源

  • 微生物
    • 市場走向
    • 市場預測
  • 哺乳動物
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依產品

  • 單株抗體
    • 市場走向
    • 市場預測
  • 疫苗
    • 市場走向
    • 市場預測
  • 重組蛋白
    • 市場走向
    • 市場預測
  • 反義、RNAi 和分子治療
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依疾病分類

  • 腫瘤學
    • 市場走向
    • 市場預測
  • 免疫系統疾病
    • 市場走向
    • 市場預測
  • 心血管疾病
    • 市場走向
    • 市場預測
  • 血液系統疾病
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：依製造業分類

  • 外包
    • 市場走向
    • 市場預測
  • 內部
    • 市場走向
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
Product Code: SR112024A3883

The global biologics market size reached US$ 349.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 699.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032. The rising prevalence of chronic diseases that necessitate more effective treatment options, continual technological advancements facilitating the development of increasingly targeted therapies, and the emergence of advanced drug delivery systems represent some of the factors that are propelling the market.

Biologics are complex molecules derived from living cells, which are used to diagnose, treat, and prevent diseases. These molecules are fundamentally different from small-molecule drugs, not only in terms of size but also in the intricacy of their structure. Characterized by a high degree of specificity, these medicinal solutions are tailored to interact with specific components within the human body, such as cells and proteins. This unique attribute enables them to target disease pathways more precisely, offering a higher potential for efficacy while minimizing side effects. The working mechanism often involves the modulation of biological pathways, either by blocking or enhancing the activity of naturally occurring molecules, to restore physiological function or eliminate pathological agents.

The global market for these complex molecules is primarily driven by the rising prevalence of chronic diseases that necessitate more effective treatment options. In line with this, continual technological advancements facilitating the development of increasingly targeted therapies, which in turn is providing an impetus to the market. Moreover, expanding healthcare budgets are resulting in a sustained demand for advanced therapeutic options, acting as a significant growth-inducing factor. In addition to this, the shift toward personalized medicine is leading to higher adoption rates of tailored therapies, thus expanding the market further. Some of the other factors contributing to the market's growth include an informed and educated patient base, the optimizing role of artificial intelligence in drug discovery, strategic collaborations between biopharmaceutical entities, and the emergence of biosimilars as off-patent versions become more accessible to a larger population.

Biologics Market Trends/Drivers:

Continual innovations in targeted therapies

A significant driver in the market for complex molecules is the continuous innovation in targeted therapies. These are therapies designed to specifically act on certain cells or molecules responsible for disease, thus increasing treatment effectiveness while minimizing side effects. Given the critical nature of diseases like cancer and autoimmune disorders, targeted therapies offer a novel and effective avenue for treatment. Extensive scientific research has enabled the understanding of disease mechanisms at the molecular level, paving the way for specialized treatments that are more effective and less toxic than traditional approaches. With increasing investments in research and development, coupled with a heightened focus on personalized medicine, these targeted therapies are poised to become mainstream. Their introduction and subsequent success can substantially elevate the demand for complex molecules, thus serving as a pivotal driver for the market.

The emergence of advanced drug delivery systems

Drug delivery systems play an increasingly crucial role in healthcare, often determining the effectiveness and patient compliance for complex molecular treatments. Innovation in this sector comes in various forms, from controlled-release mechanisms to nanotechnology-based delivery systems. Such advancements make it easier for patients to adhere to their treatment regimens, thereby improving clinical outcomes. For instance, newer delivery systems might replace daily injections with weekly or even monthly doses, substantially enhancing patient convenience and willingness to continue treatment. Significant investments are flowing into the research and development of these technologies, with the aim to maximize the therapeutic effectiveness of complex molecules. These advances in drug delivery systems are contributing immensely to the market's resilience and growth potential, fulfilling a demand for more efficient and patient-friendly therapeutic options.

Regulatory changes and harmonization

Navigating through the labyrinthine regulatory environments has long been a daunting challenge for companies in the healthcare sector. However, the current trend toward regulatory harmonization is simplifying this complex landscape. With unified or mutually recognized approval processes across different countries, market entry barriers are substantially reduced. This means that new and existing products can reach a wider patient base much faster than before. The implications are manifold: not only is there an accelerated pace at which these innovative therapies are made available to patients, but there is also a significant expansion in the geographic reach of these products. This favorable alignment of regulatory practices, by expediting approvals and broadening market access, is driving substantial and sustained growth in the global market for complex biologics molecules.

Biologics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global biologics market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on source, product, disease, and manufacturing.

Breakup by Source:

Microbial

Mammalian

Others

Microbial accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the source. This includes microbial, mammalian, and others. According to the report, microbial represented the largest segment.

The microbial segment in the global market is mainly driven by its cost-effectiveness and shorter production times compared to mammalian cell cultures. The ability of microbial systems to produce large quantities of proteins makes them an attractive option for the mass production of vaccines and insulin. Moreover, advancements in microbial fermentation technologies are making it easier to produce complex proteins. Furthermore, a wide range of approved microbial-based products and a robust pipeline of microbial-based therapies are contributing to the growth of this segment.

On the other hand, the mammalian cell culture segment is particularly suited for the production of complex biologics that require post-translational modifications. Though costlier and more time-consuming than microbial systems, mammalian cell culture remains critical for certain high-value biologics, like monoclonal antibodies. Advances in cell line development and culture methods are contributing to increased yields and efficiency. Given the specific advantages, the mammalian segment continues to maintain a substantial share in the market.

Breakup by Product:

Monoclonal Antibodies

Vaccines

Recombinant Proteins

Antisense, RNAi and Molecular Therapy

Others

Monoclonal antibodies represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the product. This includes monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAi and molecular therapy, and others. According to the report, monoclonal antibodies represented the largest segment.

The monoclonal antibodies (mAbs) segment is increasingly prominent due to their specificity in targeting a wide array of diseases including cancers, autoimmune disorders, and infections. Technological advancements in antibody engineering and hybridoma technologies have allowed for the development of highly specific and potent mAbs. Additionally, the growing number of FDA approvals for monoclonal antibodies further fuels this segment. The capacity for personalized treatment options using monoclonal antibodies also adds to its robust market potential.

On the other hand, the segments comprising vaccines, recombinant proteins, antisense RNAi, and molecular therapy, is primarily fueled by advances in genetic engineering and biotechnology. These approaches offer new avenues for treating a variety of diseases that are not adequately addressed by existing therapies. Investments in R&D are contributing to the growth of this segment, along with a growing understanding of the mechanisms behind these therapies. A robust pipeline of products in clinical trials indicates promising future prospects for these segments.

Breakup by Disease:

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

Oncology accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the disease. This includes oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others. According to the report, oncology represented the largest segment.

The oncology segment in the global market is driven by the high prevalence of cancer worldwide and an aging population more susceptible to this disease. Advancements in genomics have facilitated the development of targeted therapies for various types of cancer. The growing awareness about personalized medicine and targeted therapy in cancer treatment is also propelling this segment forward. Moreover, a strong pipeline of oncology biologics in clinical trials indicates future market growth.

On the other hand, the minor segments consisting of immunological, cardiovascular, and hematological disorders is driven by increasing incidence rates and a lack of effective treatments in some cases. Emerging biologics offer novel methods for treating these conditions, including monoclonal antibodies and recombinant proteins. The growing awareness of these innovative treatments among healthcare professionals and patients is also contributing to these segments. A strong pipeline of therapies targeting these disorders is indicative of potential growth.

Breakup by Manufacturing:

Outsourced

In-House

In-house represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the manufacturing. This includes outsourced and in-house. According to the report, in-house represented the largest segment.

The in-house segment benefits from complete control over the research, development, and manufacturing processes. Organizations are increasingly preferring in-house production to protect intellectual property rights and proprietary technologies. In-house facilities also allow for quicker adaptations to market changes and more effective implementation of quality controls. The capacity for more integrated and streamlined operations contributes to the growth of the in-house segment in the global biologics market.

On the other hand, outsourcing is an increasingly common practice due to the high costs and complexities associated with biologics production. Organizations are utilizing contract manufacturing organizations (CMOs) to lower operational costs and accelerate time-to-market. Outsourcing also allows companies to focus on core competencies like R&D while leaving production to specialized firms. Thus, the outsourced segment is seeing consistent growth in the biologics market.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest biologics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the global biologics market, primarily due to the presence of a well-established healthcare infrastructure and significant investments in biopharmaceutical research. The region is home to numerous leading biopharmaceutical companies and research institutions that drive innovation, which is creating a positive outlook for the market.

In addition to this, favorable regulatory support in the form of fast-track approvals for biologics and various financial incentives for extensive research and development (R&D) activities are also contributing to the market growth. Moreover, rising patient awareness and willingness to adopt new therapies are further fueling the demand for biologics in North America.

Furthermore, the U.S. is the largest market within the region, which is majorly buoyed by high healthcare spending, broad insurance coverage, and an increase in chronic and lifestyle-related diseases.

Competitive Landscape:

Key players in the global biologics market are aggressively focusing on innovation and research & development (R&D) activities. They are continually expanding their product pipelines to include advanced therapies in oncology, immunology, and other therapeutic areas. To meet stringent regulatory requirements, companies are investing significantly in state-of-the-art manufacturing facilities that adhere to good manufacturing practices. Collaborative agreements with academic institutions are being initiated for acquiring novel technologies. Through mergers and acquisitions, these organizations are consolidating their market presence. Strategic partnerships with smaller biotech companies are enabling the leveraging of unique skill sets and technologies. Furthermore, market leaders are engaging in patient access programs to facilitate the affordability of biologics.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amgen Inc.

AstraZeneca plc

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc

Johnson & Johnson

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Recent Developments:

In August 2023, AbbVie Inc. announced that the European Commission has approved AQUIPTA (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes AQUIPTA the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) treatment in the European Union for the preventive treatment of both chronic and episodic migraine.

In September 2023, Amgen announced that it has reached a consent order agreement with the Federal Trade Commission, resolving a pending lawsuit and paving the way for its acquisition of Horizon Therapeutics. The companies anticipate finalizing the acquisition in early Q4 2023, focusing on serving patients with rare diseases.

In August 2023, AstraZeneca plc announced that Japan's Ministry of Health, Labour and Welfare has approved the expanded use of Soliris (eculizumab) for treating pediatric patients with generalized myasthenia gravis who are resistant to other therapies. The approval follows positive outcomes from a Phase III trial, making Soliris the first targeted therapy for this condition in children and adolescents in Japan.

Key Questions Answered in This Report

  • 1. What was the size of the global biologics market in 2023?
  • 2. What is the expected growth rate of the global biologics market during 2024-2032?
  • 3. What are the key factors driving the global biologics market?
  • 4. What has been the impact of COVID-19 on the global biologics market?
  • 5. What is the breakup of the global biologics market based on the source?
  • 6. What is the breakup of the global biologics market based on the product?
  • 7. What is the breakup of the global biologics market based on the disease?
  • 8. What is the breakup of the global biologics market based on the manufacturing?
  • 9. What are the key regions in the global biologics market?
  • 10. Who are the key players/companies in the global biologics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biologics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Source

  • 6.1 Microbial
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mammalian
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Monoclonal Antibodies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Recombinant Proteins
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antisense, RNAi and Molecular Therapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Disease

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Immunological Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cardiovascular Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Hematological Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 In-House
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche Ltd
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 GlaxoSmithKline plc
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Biologics Market: Major Drivers and Challenges
  • Figure 2: Global: Biologics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Biologics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Biologics Market: Breakup by Source (in %), 2023
  • Figure 5: Global: Biologics Market: Breakup by Product (in %), 2023
  • Figure 6: Global: Biologics Market: Breakup by Disease (in %), 2023
  • Figure 7: Global: Biologics Market: Breakup by Manufacturing (in %), 2023
  • Figure 8: Global: Biologics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Biologics (Microbial) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Biologics (Microbial) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Biologics (Mammalian) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Biologics (Mammalian) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Biologics (Other Sources) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Biologics (Other Sources) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Biologics (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Biologics (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Biologics (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Biologics (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Biologics (Recombinant Proteins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Biologics (Recombinant Proteins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Biologics (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Biologics (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Biologics (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Biologics (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Biologics (Immunological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Biologics (Immunological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Biologics (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Biologics (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Biologics (Hematological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Biologics (Hematological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Biologics (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Biologics (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Biologics (Outsourced) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Biologics (Outsourced) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Biologics (In-House) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Biologics (In-House) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: North America: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: North America: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: United States: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: United States: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Canada: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Canada: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Asia-Pacific: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Asia-Pacific: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: China: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: China: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Japan: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Japan: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: India: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: India: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: South Korea: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: South Korea: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Australia: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Australia: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Indonesia: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Indonesia: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Europe: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Europe: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Germany: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Germany: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: France: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: France: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: United Kingdom: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: United Kingdom: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Italy: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Italy: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Spain: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Spain: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Russia: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Russia: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Latin America: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Latin America: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Brazil: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Brazil: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Mexico: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Mexico: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Middle East and Africa: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Middle East and Africa: Biologics Market: Breakup by Country (in %), 2023
  • Figure 87: Middle East and Africa: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Global: Biologics Industry: SWOT Analysis
  • Figure 89: Global: Biologics Industry: Value Chain Analysis
  • Figure 90: Global: Biologics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biologics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Biologics Market Forecast: Breakup by Source (in Million US$), 2024-2032
  • Table 3: Global: Biologics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Biologics Market Forecast: Breakup by Disease (in Million US$), 2024-2032
  • Table 5: Global: Biologics Market Forecast: Breakup by Manufacturing (in Million US$), 2024-2032
  • Table 6: Global: Biologics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Biologics Market: Competitive Structure
  • Table 8: Global: Biologics Market: Key Players